Chiasma Announces Using the services of of John Doyle as Main Financial Officer

The MarketWatch Information Section was not involved in the generation of this material. NEEDHAM, Mass.,…

The MarketWatch Information Section was not involved in the generation of this material.

NEEDHAM, Mass., Jan 19, 2021 (World NEWSWIRE via COMTEX) —
NEEDHAM, Mass., Jan. 19, 2021 (World NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), a professional-stage biopharmaceutical firm making use of its supply system know-how to produce and commercialize oral therapies to increase the lives of clients with uncommon ailments presently addressed with burdensome and distressing injections, as evidenced by its current phased start of MYCAPSSA(R) as the very first oral therapy for the therapy of acromegaly, right now announced the using the services of of John Doyle as its new Main Fiscal Officer, helpful right now. As formerly claimed, Mark Fitzpatrick, Chiasma’s latest President and Principal Financial Officer, will continue being with the business in a consulting role by way of June 30, 2021 to aid aid a transition of responsibilities to Mr. Doyle. Prior to becoming a member of Chiasma, Mr. Doyle served as Vice President of Finance and Trader Relations at Verastem, Inc.

“It is my enjoyment to welcome John to Chiasma, and I believe that he will make an instant effects as we continue on to execute on our U.S. business launch of MYCAPSSA,” mentioned Raj Kannan, main govt officer of Chiasma. “John provides an recognized track record of leadership and achievement, and I glance ahead to operating with him in noticing the full prospective of Chiasma.”

“I would also like to thank Mark Fitzpatrick for his devoted support to Chiasma considering that signing up for the corporation in 2015. Mark has served in a assortment of leadership roles, which includes as Main Government Officer, and his several sizeable contributions have enabled our likely potential results. On behalf of the whole Chiasma staff, I want Mark the very most effective in his long run endeavors,” Mr. Kannan additional.

“I was captivated to Chiasma because of the firm’s unwavering commitment to bring MYCAPSSA to clients in the U.S. and globally, perhaps strengthening the life of individuals suffering from acromegaly,” mentioned Mr. Doyle. “As an early professional-stage organization, I are not able to believe of a far more thrilling time to join the Chiasma crew, and I look forward to contributing to the firm’s professional and economic aims.”

Mr. Doyle joins Chiasma from Verastem, Inc., a publicly traded biopharmaceutical firm, exactly where he most not long ago served as Vice President of Finance and Trader Relations. Prior to signing up for Verastem in February 2018, he served as Head of Economical Preparing & Assessment at SimpliVity Corp., a software company that was acquired by Hewlett Packard Enterprises in February 2017. Just before that, Mr. Doyle was Director of Small business Device Financial Arranging & Examination, Early Section Division, at PAREXEL, a publicly traded pharmaceutical deal investigate organization. Earlier in his career, he served in significantly senior fiscal scheduling and assessment roles at Hologic, Inc., a publicly traded supplier of medical diagnostic, surgical and imaging products and solutions. Mr. Doyle retains a B.S. in finance from the College of Massachusetts.

About MYCAPSSA

Indication AND Crucial Security Details

Sign AND Use

MYCAPSSA (octreotide) delayed-launch capsules, for oral use, is a somatostatin analog indicated for long-expression upkeep therapy in acromegaly patients who have responded to and tolerated cure with octreotide or lanreotide.

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, which includes anaphylactic shock, have been reported in clients getting octreotide.

Critical Security Details

Warnings and Safeguards

MYCAPSSA can cause problems with the gallbladder. Watch patients periodically. Discontinue if difficulties of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels really should be monitored and treated appropriately.

Bradycardia, arrhythmia, or conduction abnormalities may well occur. Therapy with drugs that have bradycardia consequences may well require to be modified.

ADVERSE REACTIONS

The most popular adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral inflammation, blood glucose elevated, vomiting, stomach soreness, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The pursuing medications require checking and doable dose adjustment when utilised with MYCAPSSA: cyclosporine, insulin, antidiabetic medications, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and medication largely metabolized by CYP3A4. Counsel ladies to use an substitute non-hormonal process of contraception or a back again-up system when MYCAPSSA is applied with mixed oral contraceptives.

Patients using proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA could have to have amplified dosages of MYCAPSSA.

Being pregnant

Suggest premenopausal girls of the likely for an unintended pregnancy.

To report SUSPECTED ADVERSE REACTIONS, contact the merchandise information division at 1-844-312-2462 or Fda at 1-800-Food and drug administration-1088 or www.fda.gov/medwatch

The comprehensive Prescribing Information for MYCAPSSA is obtainable at www.MYCAPSSA.com.

About Acromegaly

Acromegaly generally develops when a benign tumor of the pituitary gland produces as well considerably progress hormone, eventually main to major well being troubles. Frequent capabilities of acromegaly are facial changes, intensive complications, joint suffering, impaired vision and enlargement of the fingers, toes, tongue and internal organs. Severe overall health ailments involved with the development of acromegaly involve sort 2 diabetic issues, hypertension, respiratory conditions and cardiac and cerebrovascular ailment. Chiasma estimates that about 8,000 adult acromegaly sufferers are chronically handled with somatostatin analog injections in the United States.

About Chiasma

Chiasma is a professional-stage biopharmaceutical corporation centered on producing and commercializing oral therapies to increase the life of patients who face issues connected with their existing treatment options for unusual and significant serious disorders. Employing its Transient Permeability Enhancer (TPE(R)) technological innovation platform, Chiasma seeks to produce oral prescription drugs that are currently available only as injections. In June 2020, Chiasma been given Fda approval of MYCAPSSA for lengthy-time period maintenance remedy in acromegaly sufferers who have responded to and tolerated cure with octreotide or lanreotide. MYCAPSSA, the to start with and only oral somatostatin analog permitted by the Food and drug administration, is accessible for business sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered emblems of Chiasma. For additional info, remember to visit the company’s web page at www.chiasma.com.

Ahead-Looking Statements

This launch includes “ahead-searching statements” in the this means of the Private Securities Litigation Reform Act of 1995, which includes, but not constrained to, statements relating to the potential industrial success of MYCAPSSA. These types of statements are topic to numerous vital things, dangers and uncertainties, numerous of which are further than the company’s manage, that might trigger precise gatherings or results to vary materially from the company’s existing expectations. Management’s anticipations and, for that reason, any ahead-searching statements in this press launch could be afflicted by risks and uncertainties. For a dialogue of these pitfalls and uncertainties, and other critical components, any of which could trigger the company’s actual results to differ from all those contained in the ahead-on the lookout statements, see the part entitled “Threat Elements” in Chiasma’s Quarterly Report on Kind 10-Q for the quarter finished September 30, 2020, and in subsequent filings with the Securities and Trade Fee. All information in this push launch is as of the date of the release, and Chiasma undertakes no obligation to update this information unless necessary by law.

Contacts:

Investor Relations and Company Communications:
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
[email protected]

Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
[email protected]

COMTEX_377896379/2471/2021-01-19T07:00:26

Is there a problem with this press release? Get hold of the resource company Comtex at [email protected] You can also get in touch with MarketWatch Client Service by way of our Customer Centre.

(C) Copyright 2021 GlobeNewswire, Inc. All legal rights reserved.

The MarketWatch Information Department was not concerned in the generation of this written content.